Motus GI Holdings, Inc. Announces Pricing of $5.0 Million Public Offering
FORT LAUDERDALE, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc. (Nasdaq:MOTS, or “Motus GI” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today the pricing of a public offering of 3,333,334 shares of common stock (or pre-funded warrants in lieu thereof), Series A common warrants to purchase up to 3,333,334 shares of common stock, and Series B common warrants to purchase up to 3,333,334 shares of common stock, at a combined public offering price of $1.50 per share (or pre-funded warrant in lieu thereof) and Series A common warrant and Series B common warrant, each to purchase one share of common stock, for aggregate gross proceeds of approximately $5.0 million, before deducting placement agent fees and other offering expenses. The Series A warrants will have an exercise price of $1.50 per share, will be exercisable immediately, and will expire five years from the initial issuance date. The Series B warrants will have an exercise price of $1.50 per share, will be exercisable immediately, and will expire eighteen months from the initial issuance date. The pre-funded warrants and accompanying common warrants are substantially identical, except that each pre-funded warrant is immediately exercisable for one share of common stock at an exercise price of $0.0001, the purchase price for a pre-funded warrant and accompanying common warrants is the public offering price minus $0.0001 and the pre-funded warrants do not expire until exercised.
Related news for (MOTS)
- Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds
- 24/7 Market News Snapshot 21 Feb 2024
- Motus GI Bouncing off Its 52-Week Low
- Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract